AU2006280144B2 - Vaccination against dengue virus infection - Google Patents

Vaccination against dengue virus infection Download PDF

Info

Publication number
AU2006280144B2
AU2006280144B2 AU2006280144A AU2006280144A AU2006280144B2 AU 2006280144 B2 AU2006280144 B2 AU 2006280144B2 AU 2006280144 A AU2006280144 A AU 2006280144A AU 2006280144 A AU2006280144 A AU 2006280144A AU 2006280144 B2 AU2006280144 B2 AU 2006280144B2
Authority
AU
Australia
Prior art keywords
vaccine
dengue
yellow fever
virus
chimeric flavivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006280144A
Other languages
English (en)
Other versions
AU2006280144A1 (en
Inventor
Thomas H. Ermak
Remi Forrat
Farshad Guirakhoo
Niranjan Kanesa-Thasan
Jean Lang
Thomas P. Monath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Sanofi Pasteur Biologics LLC
Original Assignee
Sanofi Pasteur SA
Sanofi Pasteur Biologics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA, Sanofi Pasteur Biologics LLC filed Critical Sanofi Pasteur SA
Publication of AU2006280144A1 publication Critical patent/AU2006280144A1/en
Assigned to SANOFI PASTEUR SA, SANOFI PASTEUR BIOLOGICS CO. reassignment SANOFI PASTEUR SA Amend patent request/document other than specification (104) Assignors: ACAMBIS INC., SANOFI PASTEUR SA
Application granted granted Critical
Publication of AU2006280144B2 publication Critical patent/AU2006280144B2/en
Priority to AU2012216852A priority Critical patent/AU2012216852A1/en
Assigned to SANOFI PASTEUR SA, SANOFI PASTEUR BIOLOGICS, LLC reassignment SANOFI PASTEUR SA Request to Amend Deed and Register Assignors: SANOFI PASTEUR BIOLOGICS CO., SANOFI PASTEUR SA
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006280144A 2005-08-10 2006-08-09 Vaccination against dengue virus infection Ceased AU2006280144B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012216852A AU2012216852A1 (en) 2005-08-10 2012-09-14 Vaccination against dengue virus infection

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70703805P 2005-08-10 2005-08-10
US60/707,038 2005-08-10
US71944805P 2005-09-22 2005-09-22
US60/719,448 2005-09-22
PCT/US2006/030846 WO2007021672A2 (en) 2005-08-10 2006-08-09 Vaccination against dengue virus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012216852A Division AU2012216852A1 (en) 2005-08-10 2012-09-14 Vaccination against dengue virus infection

Publications (2)

Publication Number Publication Date
AU2006280144A1 AU2006280144A1 (en) 2007-02-22
AU2006280144B2 true AU2006280144B2 (en) 2012-06-14

Family

ID=37758084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006280144A Ceased AU2006280144B2 (en) 2005-08-10 2006-08-09 Vaccination against dengue virus infection

Country Status (12)

Country Link
US (1) US20080193477A1 (enExample)
EP (1) EP1924280A4 (enExample)
JP (1) JP5227172B2 (enExample)
AR (1) AR055603A1 (enExample)
AU (1) AU2006280144B2 (enExample)
BR (1) BRPI0614265A2 (enExample)
CA (1) CA2618783A1 (enExample)
IL (1) IL189329A (enExample)
MY (1) MY151051A (enExample)
NO (1) NO20081127L (enExample)
TW (1) TW200740458A (enExample)
WO (1) WO2007021672A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US9211323B2 (en) 2009-06-01 2015-12-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
CA2878599A1 (en) 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
CA3177572C (en) 2013-03-15 2026-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
SG10201807826XA (en) * 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
KR20230154072A (ko) 2014-09-26 2023-11-07 세퀴러스 유케이 리미티드 면역손상된 대상체의 백신 접종
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
US11268071B2 (en) 2017-03-30 2022-03-08 Merck Sharp And Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
AU2018346724B2 (en) 2017-10-05 2025-01-09 Sanofi Pasteur Compositions for booster vaccination against dengue
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
MX2022001742A (es) 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
CN120225693A (zh) 2022-11-18 2025-06-27 武田疫苗股份有限公司 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
US6966281B1 (en) * 2004-05-05 2005-11-22 Hale James R Internal combustion device and methods of use
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GUIRAKHOO, F. et al. J. Virol. (2000) vol. 74, pages 5477-5485 *
GUIRAKHOO, F. et al. J. Virol. (2001) vol. 75, pages 7290-7304 *
GUIRAKHOO, F. et al. J. Virol. (2004) vol. 78, pages 4761-4775 *
KANESA-THASAN, N. et al. Am. J. Trop. Med. Hyg. (2003) vol. 69, pages 32-38 *
MONATH, T. Expert. Rev. Vaccines (2005) vol. 4, pages 553-574 *
SABCHAREON, A. Pediatr. Infect. Dis. J. (2004) vol. 23, pages 99-109 *

Also Published As

Publication number Publication date
IL189329A0 (en) 2008-06-05
JP5227172B2 (ja) 2013-07-03
IL189329A (en) 2015-07-30
AR055603A1 (es) 2007-08-29
JP2009504654A (ja) 2009-02-05
TW200740458A (en) 2007-11-01
WO2007021672A2 (en) 2007-02-22
EP1924280A4 (en) 2008-12-10
NO20081127L (no) 2008-05-07
CA2618783A1 (en) 2007-02-22
BRPI0614265A2 (pt) 2011-03-22
EP1924280A2 (en) 2008-05-28
AU2006280144A1 (en) 2007-02-22
US20080193477A1 (en) 2008-08-14
MY151051A (en) 2014-03-31
WO2007021672A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
US20080193477A1 (en) Vaccination Against Dengue Virus Infection
JP6830118B2 (ja) ワクチン組成物
Guirakhoo et al. Live attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all
JP2022089964A (ja) 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
US20130095136A1 (en) Tetravalent Dengue Vaccines
JP5269796B2 (ja) ４種のデング血清型に対する免疫付与の方法
US20150265695A1 (en) Vaccine compositions for prevention against dengue virus infection
CN101489585A (zh) 针对登革病毒四种血清型的免疫接种方法
US9861692B2 (en) Dengue virus vaccine compositions and methods of use thereof
US10449243B2 (en) Dengue virus vaccine compositions and methods of use thereof
US20170114330A1 (en) Chimeric west nile/dengue viruses and methods of use
CN101287490B (zh) 对抗登革热病毒感染的疫苗接种
AU2012216852A1 (en) Vaccination against dengue virus infection
MX2008001978A (en) Vaccination against dengue virus infection
US20220175908A1 (en) Methods for Inducing a Safe Immune Response Against Polio Virus

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE EXAMINATION RESPONSE FEE HAS BEEN EXTENDED TO 11 AUG 2012 .

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired